28466-62-8

Basic information

• Product Name: 1-benzylpyrazol-4-amine
• Synonyms: 1-benzylpyrazol-4-amine;1-benzyl-1H-pyrazol-4-amine(SALTDATA: HCl);1-N-Benzyl-4-amino-1H-pyrazole;[1-(benzyl)pyrazol-4-yl]amine;1-(phenylmethyl)-4-pyrazolamine;1-(phenylmethyl)pyrazol-4-amine;4-Amino-1-benzylpyrazole;4-Ammino-1-benzilpirazolo [Italian]
• CAS NO: 28466-62-8
• Molecular Formula: C₁₀H₁₁N₃
• Molecular Weight: 173.22
• Mol File: 28466-62-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 369.4°Cat760mmHg
• Flash Point: 177.2°C
• Appearance: /
• Density: 1.16g/cm³
• Vapor Pressure: 1.19E-05mmHg at 25°C
• Refractive Index: 1.622
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 3.60±0.11(Predicted)
• CAS DataBase Reference: 1-benzylpyrazol-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzylpyrazol-4-amine(28466-62-8)
• EPA Substance Registry System: 1-benzylpyrazol-4-amine(28466-62-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 28466-62-8(Hazardous Substances Data)

Usage

General Description

1-Benzylpyrazol-4-amine is an organic compound that primarily serves as a chemical reagent in various scientific and industrial applications. This chemical is notable for containing a pyrazole ring, which is a key structural component in many pharmaceutical drugs, such as celecoxib and famotidine. The geometric arrangement and specific functionalities of the molecules allow for a broad range of reactions, making 1-benzylpyrazol-4-amine particularly valuable in the synthesis of more complex organic compounds. However, as with any chemical substance, it is important to handle it responsibly due to potential hazards associated with improper usage.

InChI:InChI=1/C10H11N3/c11-10-6-12-13(8-10)7-9-4-2-1-3-5-9/h1-6,8H,7,11H2

Upstream product

• 100-39-0 benzyl bromide 
• 88095-61-8 1-benzyl-4-nitro-1H-pyrazole 

Downstream Products

• 1174665-60-1 2-[5-(1-benzyl-1H-pyrazol-4-ylcarbamoyl)-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-indole-1-carboxylic acid tert-butyl ester 
• 1174665-75-8 2-[5-(1-benzyl-1H-pyrazol-4-ylcarbamoyl)-2-oxo-1-(2-trimethylsilanyl-ethoxymethyl)-1,2-dihydro-pyridin-3-yl]-5-(4-tert-butoxycarbonyl-piperazin-1-ylmethyl)-indole-1-carboxylic acid tert-butyl ester 
• 1258557-69-5 (1S,2S,3R,4R)-3-({2-[(1-benzyl-1H-pyrazol-4-yl)amino]-5-chloropyrimidin-4-yl}amino)bicyclo[2.2.1]hept-5-ene-2-carboxamide 

Relevant articles and documents

Design and synthesis of anti-tumor compounds containing ferulic acid-pyrazole skeleton

The invention discloses design and a preparation method of an anti-tumor compound containing a ferulic acid-pyrazole skeleton. The structure of the anti-tumor compound is shown as a formula in the specification.

Design, synthesis, and biological evaluation of pyrazole derivatives containing acetamide bond as potential BRAFV600E inhibitors

With the increasingly acquired resistance, relapse and side effects of known marketed BRAFV600E inhibitors, it's significant to design the more effective and novel drugs. In this study, a series of novel pyrazole derivatives containing acetamid

Tetrahydroindazoles as interleukin-2 inducible T-cell kinase inhibitors. Part II. Second-generation analogues with enhanced potency, selectivity, and pharmacodynamic modulation in vivo

The medicinal chemistry community has directed considerable efforts toward the discovery of selective inhibitors of interleukin-2 inducible T-cell kinase (ITK), given its role in T-cell signaling downstream of the T-cell receptor (TCR) and the implications of this target for inflammatory disorders such as asthma. We have previously disclosed a structure- and property-guided lead optimization effort which resulted in the discovery of a new series of tetrahydroindazole-containing selective ITK inhibitors. Herein we disclose further optimization of this series that resulted in further potency improvements, reduced off-target receptor binding liabilities, and reduced cytotoxicity. Specifically, we have identified a correlation between the basicity of solubilizing elements in the ITK inhibitors and off-target antiproliferative effects, which was exploited to reduce cytotoxicity while maintaining kinase selectivity. Optimized analogues were shown to reduce IL-2 and IL-13 production in vivo following oral or intraperitoneal dosing in mice.